The Pittsburgh Business Times is reporting on the Regenerate 2004 conference on regenerative medicine. As I often point out, the health of a large field in medicine can be estimated from the number of conferences and new buildings. Regenerative medicine and tissue engineering are doing well by all accounts. Assuming that governments stop blocking stem cell research and therapeutic cloning, the next decade should see a range of regenerative therapies hit the market. I predict that cures for heart disease and diabetes will be amongst the first benefits to emerge from this industry, accompanied by the ability to completely regenerate damage to organs like bones, muscle, skin, and the heart and liver.